J Mellergård1, A Tisell2,3, I Blystad3,4, A Grönqvist2, K Blennow5, B Olsson5, C Dahle6, M Vrethem1,7, P Lundberg2,3,4, J Ernerudh6. 1. Department of Neurology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 2. Department of Radiation Physics and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 3. Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden. 4. Department of Radiology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 5. Clinical Neurochemistry Laboratory, Institution of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden. 6. Department of Clinical Immunology and Transfusion Medicine and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 7. Department of Clinical Neurophysiology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Abstract
BACKGROUND AND PURPOSE: Brain atrophy is related to clinical deterioration in multiple sclerosis (MS) but its association with intrathecal markers of inflammation or neurodegeneration is unclear. Our aim was to investigate whether cerebrospinal fluid (CSF) markers of inflammation or neurodegeneration are associated with brain volume change in natalizumab-treated MS and whether this change is reflected in non-lesional white matter metabolites. METHODS: About 25 patients with natalizumab-treated MS were followed for 3 years with assessment of percentage brain volume change (PBVC) and absolute quantification of metabolites with proton magnetic resonance spectroscopy (1 H MRS). Analyses of inflammatory [interleukin 1β (IL-1β), IL-6, C-X-C motif chemokine 8 (CXCL8), CXCL10, CXCL11, C-C motif chemokine 22] and neurodegenerative [neurofilament light protein (NFL), glial fibrillary acidic protein, myelin basic protein, tau proteins] markers were done at baseline and 1-year follow-up. RESULTS: The mean decline in PBVC was 3% at the 3-year follow-up, although mean 1 H MRS metabolite levels in non-lesional white matter were unchanged. CSF levels of NFL and tau at baseline correlated negatively with PBVC over 3 years (r = -0.564, P = 0.012, and r = -0.592, P = 0.010, respectively). CONCLUSIONS: A significant 3-year whole-brain atrophy was not reflected in mean metabolite change of non-lesional white matter. In addition, our results suggest that CSF levels of NFL and tau correlate with brain atrophy development and may be used for evaluating treatment response in inflammatory active MS.
BACKGROUND AND PURPOSE:Brain atrophy is related to clinical deterioration in multiple sclerosis (MS) but its association with intrathecal markers of inflammation or neurodegeneration is unclear. Our aim was to investigate whether cerebrospinal fluid (CSF) markers of inflammation or neurodegeneration are associated with brain volume change in natalizumab-treated MS and whether this change is reflected in non-lesional white matter metabolites. METHODS: About 25 patients with natalizumab-treated MS were followed for 3 years with assessment of percentage brain volume change (PBVC) and absolute quantification of metabolites with proton magnetic resonance spectroscopy (1 H MRS). Analyses of inflammatory [interleukin 1β (IL-1β), IL-6, C-X-C motif chemokine 8 (CXCL8), CXCL10, CXCL11, C-C motif chemokine 22] and neurodegenerative [neurofilament light protein (NFL), glial fibrillary acidic protein, myelin basic protein, tau proteins] markers were done at baseline and 1-year follow-up. RESULTS: The mean decline in PBVC was 3% at the 3-year follow-up, although mean 1 H MRS metabolite levels in non-lesional white matter were unchanged. CSF levels of NFL and tau at baseline correlated negatively with PBVC over 3 years (r = -0.564, P = 0.012, and r = -0.592, P = 0.010, respectively). CONCLUSIONS: A significant 3-year whole-brain atrophy was not reflected in mean metabolite change of non-lesional white matter. In addition, our results suggest that CSF levels of NFL and tau correlate with brain atrophy development and may be used for evaluating treatment response in inflammatory active MS.
Authors: Sarah Harris; Giancarlo Comi; Bruce A C Cree; Douglas L Arnold; Lawrence Steinman; James K Sheffield; Harry Southworth; Ludwig Kappos; Jeffrey A Cohen Journal: Eur J Neurol Date: 2021-08-23 Impact factor: 6.288
Authors: Mattia Rosso; Cindy T Gonzalez; Brian C Healy; Shrishti Saxena; Anu Paul; Kjetil Bjornevik; Jens Kuhle; Pascal Benkert; David Leppert; Charles Guttmann; Rohit Bakshi; Howard L Weiner; Tanuja Chitnis Journal: Ann Clin Transl Neurol Date: 2020-05-25 Impact factor: 4.511
Authors: Irene Håkansson; Anders Tisell; Petra Cassel; Kaj Blennow; Henrik Zetterberg; Peter Lundberg; Charlotte Dahle; Magnus Vrethem; Jan Ernerudh Journal: J Neuroinflammation Date: 2018-07-18 Impact factor: 8.322
Authors: Maria Pia Sormani; Dieter A Haering; Harald Kropshofer; David Leppert; Uma Kundu; Christian Barro; Ludwig Kappos; Davorka Tomic; Jens Kuhle Journal: Ann Clin Transl Neurol Date: 2019-05-28 Impact factor: 4.511
Authors: José Luis Molinuevo; Scott Ayton; Richard Batrla; Martin M Bednar; Tobias Bittner; Jeffrey Cummings; Anne M Fagan; Harald Hampel; Michelle M Mielke; Alvydas Mikulskis; Sid O'Bryant; Philip Scheltens; Jeffrey Sevigny; Leslie M Shaw; Holly D Soares; Gary Tong; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow Journal: Acta Neuropathol Date: 2018-11-28 Impact factor: 17.088